Talking Biotech with Dr. Kevin Folta Colabra
-
- Science
-
Talking Biotech is a weekly podcast that uncovers the stories, ideas and research of people at the frontier of biology and engineering.
Each episode explores how science and technology will transform agriculture, protect the environment, and feed 10 billion people by 2050.
Interviews are led by Dr. Kevin Folta, a professor of molecular biology and genomics.
-
The FDA Regulatory Ecosystem- Expert Panel Discusses the Process
How do new drug applications move forward to approval? Four experts discuss the partnership between the FDA, the drug developer, and the data needed to move a product forward. It is a surprising discussion that reveals the depth of the FDA process. Joined by Dr. Debra Webster, Dr. Julia Marre, Dr. Michael Matthews and Dr. Jonathan Helfgott.
-
The Psychology of Risk - Dr. Felicia Wu
We live in amazing times of technological advance, but how are the real benefits of new tech lost to an inflated sense of risk? Dr. Felicia Wu from Michigan State University shares her expertise in describing the psychological basis of risk and applying it to questions like glyphosate and aspartame.
-
Restoring the Forest with GE American Chestnut - Dr. Andy Newhouse and Erik Carlson
This is an update on the American Chestnut Restoration Project, as discussed previously on the podcast. The American Chestnut dominated the forests of Appalachia until an imported fungus destroyed the entire range. Efforts to restore the chestnut and its ecology have employed a biotechnology approach, integrating a gene from wheat that limits the mechanism the fungus uses to attack the tree. Dr. Andy Newhouse and Erik Carlson join the podcast to discuss progress in the project.
-
Addressing Disparities in Women's Healthcare - Sabrina Johnson, CEO Daré Bioscience
Despite being over half of the population women's health care lags behind other areas of drug development. The problem is caused by many facets, but is augmented by the fact that many of the conditions are not life threatening or are functions of aging. Sabrina Johnson, CEO of Daré Bioscience, discusses how the disparity exists, the pipeline of drugs that seek to mitigate female-specific conditions, and how smaller, leaner businesses can have significant impacts in this space.
-
Return of Talking Biotech; Stories in the News
After a three month hiatus the Talking Biotech Podcast is back. Today's episode is a visit with Colarbra CEO Aoi Senju about his view for the podcast, followed by synopsis of three major news stories that broke since the last Talking Biotech Podcast. The new format includes a video component, and I'll be speaking with panels and also discussing recent news stories. It is an exciting opportunity to capture a new audience, expand listenership, and provide new levels of programming to the popular format. Thank you for your patience and I hope you enjoy the new episodes. Kevin
-
Temporary Hiatus, Changes Coming!
After 8.5 years of weekly podcasts I'm going to take a 5 week break and plan new episodes for 2024. I'm going through a medical glitch that has me unable to do my normal work. On top of this we're going to switch to an audio plus video format to find a wider audience. So check back in 2024 for the next episode. Have a great rest of 2023, thank you for listening, and looking forward to better times.
Customer Reviews
Great Podcast!
There are not enough fantastic scientific resources like this. It is unbiased, accurate and educational. In this world of science misinformation, I applaud Dr. Flora for being a steady voice for objective evidence-based reason.
Great biotech podcast with wide array of topics
This is a fantastic podcast that looks at a broad array of biotech topics ranging from medicine, genetics, agriculture, conservation, and many more. The conversations start at a high enough level to be of value to laymen and non experts but also drill down to specifics that can be deeply informative to those working in biotech. Overall, a really great podcast that anyone interested in or trying to stay up to date with the rapidly evolving biotech landscape should follow
Follow “the science”
the e-mails show that Folta did receive an unrestricted US$25,000 grant last year from Monsanto, which noted that the money “may be used at your discretion in support of your research and outreach projects”. Folta says that the funds are earmarked for a proposed University of Florida programme on communicating biotechnology.